1. Pharmacological study of a new hypoglycaemic sulphonamide: glisoxepid (RP 22410)
- Author
-
Ribes G, Agot H, Loubatières Al, Alric R, and Mariani Mm
- Subjects
Drug ,Blood Glucose ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,media_common.quotation_subject ,Tolbutamide ,Administration, Oral ,Pharmacology ,In Vitro Techniques ,Neogenesis ,Islets of Langerhans ,Mice ,Dogs ,Pancreatectomy ,Oral administration ,Internal medicine ,Insulin Secretion ,Internal Medicine ,medicine ,Animals ,Insulin ,Oxazoles ,Pancreas ,media_common ,geography ,geography.geographical_feature_category ,biology ,business.industry ,Azepines ,biology.organism_classification ,Islet ,In vitro ,Stimulation, Chemical ,Rats ,Perfusion ,medicine.anatomical_structure ,Endocrinology ,Sulfonylurea Compounds ,Injections, Intravenous ,business ,medicine.drug - Abstract
Glisoxepid or RP 22410 is a new very active hypoglycaemic sulphonylurea. In the normal conscious dog, RP 22410 administered intravenously was 81 or 131 times more active than tolbutamide, depending on whether the dose is expressed in grams or in moles. The hypoglycaemic effect did not occur in the totally pancreatectomized dog. — RP 22410 stimulated insulin secretion.In vivo in the anaesthetized or conscious dog, the action of the drug (whether it be administered intravenously or orally) resulted in a rapid and considerable increase of the amount of insulin secreted by the pancreas. This action lasted several hours.In vitro the direct action of the product on the pancreas was demonstrated on the isolated and perfused rat pancreas, even at very low concentrations. — In the mouse, prolonged oral administration of RP 22410 stimulated neogenesis of the islets of Langerhans and of the beta cells. It therefore possesses betacytotrophic action.
- Published
- 1972